IRIS
IAFFALDANO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.803
EU - Europa 827
AS - Asia 215
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 4
OC - Oceania 2
AF - Africa 1
Totale 4.857
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.799
SE - Svezia 338
IT - Italia 216
CN - Cina 172
GB - Regno Unito 88
FI - Finlandia 41
DE - Germania 32
UA - Ucraina 32
FR - Francia 27
BE - Belgio 22
VN - Vietnam 14
SG - Singapore 9
CZ - Repubblica Ceca 6
IN - India 6
SA - Arabia Saudita 6
IE - Irlanda 5
EU - Europa 3
IL - Israele 3
IR - Iran 3
NL - Olanda 3
PT - Portogallo 3
RO - Romania 3
A1 - Anonimo 2
BR - Brasile 2
CA - Canada 2
ES - Italia 2
RU - Federazione Russa 2
AR - Argentina 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
EG - Egitto 1
GL - Groenlandia 1
GR - Grecia 1
IS - Islanda 1
JP - Giappone 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
Totale 4.857
Salva come PNG Salva come JPEG
Città #
Fairfield 616
Chandler 431
Woodbridge 378
Ashburn 325
Nyköping 270
Houston 262
Seattle 251
Ann Arbor 240
Cambridge 211
Wilmington 172
Lawrence 80
Jacksonville 75
Roxbury 71
Beijing 58
Bari 55
Des Moines 48
Boardman 41
Nanjing 41
Princeton 37
New York 36
Brooklyn 35
Inglewood 30
San Diego 26
Brussels 22
Norwalk 19
Paris 19
London 14
Dong Ket 13
Tianjin 12
Bisceglie 11
Shenyang 11
Nanchang 10
Dearborn 9
Munich 9
Milan 8
Washington 8
Hebei 7
Taranto 7
Brno 6
Falls Church 6
Jiaxing 6
Kilburn 6
Catania 5
Dublin 5
Grottaglie 5
Guangzhou 5
Imbersago 5
Jeddah 5
Singapore 5
Changsha 4
Los Angeles 4
Pune 4
Redwood City 4
Sabaudia 4
West Jordan 4
Helsinki 3
Hounslow 3
Rome 3
Villacidro 3
Amsterdam 2
Andria 2
Auburn Hills 2
Augusta 2
Bolsena 2
Chicago 2
Chieti 2
Chiswick 2
Dallas 2
Edinburgh 2
Florence 2
Grafing 2
Indiana 2
Jinan 2
Lviv 2
New Bedfont 2
Noicattaro 2
Nutley 2
Palermo 2
Phoenix 2
Shanghai 2
St Albans 2
Stockholm 2
Tappahannock 2
Terlan 2
Trani 2
Triggiano 2
Acton 1
Albinea 1
Atlanta 1
Auckland 1
Bologna 1
Boydton 1
Bucharest 1
Cairo 1
Castel Maggiore 1
Chengdu 1
Chizhou 1
Clearwater 1
Formia 1
Formosa do Rio Preto 1
Totale 4.131
Salva come PNG Salva come JPEG
Nome #
Prognostic indicators in pediatric clinically isolated syndrome 130
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 126
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 120
null 109
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 106
Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial 106
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 102
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 101
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 100
Treating multiple sclerosis with natalizumab. 98
Multiple sclerosis registries in Europe – An updated mapping survey 97
Treatment decisions in multiple sclerosis-insights from real-world observational studies 93
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 92
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 92
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 89
Safety profile of Tysabri: international risk management plan 85
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 85
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 84
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 84
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 84
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 81
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 80
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 80
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients 79
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 78
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 78
Predictors and dynamics of postpartum relapses in women with multiple sclerosis. 74
null 73
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 72
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 72
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 72
Emotional and neutral verbal memory impairment in Multiple Sclerosis 70
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 69
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 68
null 68
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 68
null 67
Low serum urate levels are associated to female gender in multiple sclerosis patients. 66
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients 65
null 65
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 62
null 56
null 55
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study 55
Sclerosi Multipla e Lavoro: dati preliminari 53
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 51
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis 50
Geographical variations in sex ratio trends over time in multiple sclerosis. 49
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 49
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 48
Natalizumab reduces serum pro-angiogenic activity in MS patients 47
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 46
Dengue fever in a multiple sclerosis patient taking Ocrelizumab 46
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 45
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis 43
Disability assessment using Google Maps 42
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 41
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 41
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 38
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network 37
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 36
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 36
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 35
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study 34
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis 33
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 33
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 31
Assessing long-term effectiveness of MS treatment - a matter of debate 31
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 29
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 27
Risk of Getting COVID-19 in People With Multiple Sclerosis 25
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 25
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 24
Serum N-acetyl aspartate (NAA) levels differ in multiple sclerosis (MS) and neuromyelitis optica (NMO). 24
Anxiety state affects information processing speed in patients with multiple sclerosis 24
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 24
A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis 24
Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment 20
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 19
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 19
Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender 19
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 19
null 18
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 18
Real-life impact of early interferonbeta therapy in relapsing multiple sclerosis 16
Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate 14
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 12
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis. 11
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network 10
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 10
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register 9
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register 7
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 6
Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register 5
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 5
Signs and symptoms of COVID-19 in patients with multiple sclerosis 5
Big Multiple Sclerosis Data network: an international registry research network 3
Increasing age at disability milestones among MS patients in the MSBase Registry. 3
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 2
Multiple Sclerosis Progression and Relapse Activity in Children 2
Totale 5.129
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019137 0 0 0 0 0 0 0 0 0 0 0 137
2019/20201.133 158 61 30 95 127 68 103 119 132 86 122 32
2020/2021970 53 52 81 117 98 83 68 75 64 109 90 80
2021/2022754 61 72 21 23 49 87 34 44 51 48 117 147
2022/20231.102 158 170 88 87 128 131 20 120 151 4 26 19
2023/2024442 41 54 29 24 41 95 16 25 6 30 11 70
Totale 5.146